Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sumitomo Pharma's $1.7 billion deal to absorb Myovant Sciences ends a years-long ownership uncertainty around the relugolix franchise, which Sumitomo helped…
Myovant Sciences and Sumitovant Biopharma today announced a definitive merger agreement under which Sumitovant will acquire all outstanding common shares of…
Myovant reported third quarter fiscal 2022 net product revenue of $58.6 million, up 116% year over year, driven by Orgovyx growth in advanced prostate cancer…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Sumitovant Biopharma agreed to acquire all outstanding Myovant shares it did not already own (Sumitomo held ~52%) at $27.00/share cash, valuing the minority at $1.7B and total company at $2.9B. The deal was a definitive agreement on Oct 24, 2022 (revised up from prior offer).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sumitomo Pharma / Sumitovant Biopharma / Myovant Sciences Ltd. (this deal) | 2022 | $1.7B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2022 deals · Oncology deals